
The costs of cancer care are rising, and spending on expensive innovative zzso agents is likely to come under scrutiny as health care zzso are confronted by the challenge of resource limits in the face of infinite zzso zzso costs account for the major part of total attributable costs of cancer and are dominated by the cost of mortality in individuals of working age (who therefore do not contribute to economic zzso Although cancer is a leading cause of morbidity and premature zzso in 2007, it was estimated that cancer accounted for only around zzso of the total health care costs in zzso It is estimated that cancer drug costs constitute around zzso of total direct cancer costs and zzso of the costs of all zzso Countries vary in their zzso of novel zzso zzso However, even in zzso leading nation for the use of these zzso costs of innovative zzso drugs accounted for zzso of total health care expenditure in zzso zzso data suggest that novel therapies have contributed zzso with advances in screening and other aspects of care) to improvements in survival from zzso If this is the case, then the potential reduction in the associated indirect costs could exceed the direct costs associated with the zzso of innovative drug zzso Further research is required to establish the costs and benefits of novel agents in routine zzso 

